Anthony Olszanski, MD, RPh

Anthony Olszanski, MD
(4.9/5.0)
85 Patient Satisfaction Ratings
Request an Appointment

Clinical Locations

Associate Professor, Department of Hematology/Oncology

Vice Chair, Clinical Research, Department of Hematology/Oncology

Chief, Section of Solid Tumor Oncology

Co-Director, Melanoma and Skin Cancer Program

Director, Early Clinical Drug Development Phase 1 Program ​

National Comprehensive Cancer Network (NCCN)

  • International Program Steering Committee
  • Melanoma Panel
  • NCCN ORP Investigator Steering Committee
  • Executive Editorial Board

Treatment Focus

Early Clinical Drug Development/Phase 1 Trials; Melanoma and skin cancer; Lung cancers; Gastrointestinal cancers

Research Program

Treatment Philosophy

I believe that the path towards treating any disease is best navigated by thoroughly understanding not only the disease, but also the patient. Good communication between a physician and a patient is especially critical in the treatment of cancer. Each patient has a right to be both respected and heard. In addition, relying on a team of experts to help manage the complexities of treating cancer is essential for success. As a physician, I strive to provide personalized and scientifically sound care to each of my patients.

My medical career started out as a pharmacist, specializing in oncology, where I prepared chemotherapy regimens and studied the effects the body has on drugs (pharmacokinetics).  When I went to medical school, it was for the sole purpose of eventually becoming an oncologist. During my hematology/oncology and clinical pharmacology fellowships, I spent a great deal of time in early clinical development, with a goal of finding new effective therapies for patients with cancer.  I honed my knowledge of drug discovery by spending five years in the pharmaceutical industry where I led multiple programs aimed at treating patients with cancers that didn’t respond to traditional chemotherapy. Today, my interests focus on early drug development for all types of cancers, and understanding how each medication may best be used. In addition I specifically focus on the treatment of lung cancer, skin cancers including melanoma, and gastrointestinal malignancies.

In many situations, the best medical care a patient with cancer can get is on a clinical trial. These clinical trials offer patients potentially promising new therapies and very close follow up supplied by a team of experts. Fox Chase Cancer Center, with its leading-edge technology and dedicated medical professionals, offers numerous clinical trials and is helping to advance the care of all patients with cancer.

The staff at Fox Chase Cancer Center continually impress me with their unified commitment towards reducing the burden of cancer. When you step through the doors at Fox Chase Cancer Center, it is obvious that focusing on the patient is the top priority. I am proud to be a member of the caring community at FCCC, where oncology research and science is tailored and personalized for each patient.

Educational Background

  • Fellow, Clinical Pharmacology/Toxicology, Oncology Phase I Program, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 2002-2004
  • Fellow, Hematology/Oncology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 1999-2002
  • Resident, Internal Medicine, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 1996-1999
  • Resident, Biostatistics, Center for Evaluative Clinical Sciences, Dartmouth Medical School, Hanover, NH, 2003
  • MD, University of Medicine and Dentistry of New Jersey, Newark, NJ, 1996
  • BS, Pharmacy, University of Montana, Missoula, MT, 1990

Certifications

  • Board Certified in Medical Oncology
  • Board Certified in Clinical Pharmacology

Memberships

  • National Comprehensive Cancer Network (NCCN)
    • International Program Steering Committee
    • Melanoma Panel
    • NCCN ORP Investigator Steering Committee
    • Executive Editorial Board
  • American Board of Clinical Pharmacology
  • American Society of Clinical Oncology

Honors & Awards

  • Robert L. Krigel Memorial Award: Excellence in Teaching and Clinical Oncology, 2014

Joanne Gannon

  • Melanoma

In 2014, just after turning 67, I noticed a spot on my leg. When I went to see a dermatologist near where I live in Forked River, New Jersey, he diagnosed me with melanoma. I was really surprised. I’m dark-skinned—Italian—and melanoma is not common in dark-skinned people. I never used tanning beds or laid out a lot in the sun, but I guess it can happen to anyone.

VIEW PATIENT STORY

Nancy Finn

  • Melanoma

I’m 64 years old and live in Yardley, Pennsylvania, which is just north of Philadelphia. I’m retired now, but I spent many years doing social justice work and fundraising for nonprofits. It was a busy life, which is why, when I developed a lesion on my left shin, I didn’t pay attention to it. Then, literally overnight in 2015, it got really bad. I wound up in the hospital, where they diagnosed me with stage IV melanoma—skin cancer.

VIEW PATIENT STORY

Tiffany Fagnani

  • Lung Cancer

I am 40 years old and currently live in Mechanicsburg, Pennsylvania. Although I work as a case manager for an insurance company now, I was previously employed as a full-time nurse. I have always been a busy person with plenty on my plate, so when I started feeling tired and losing weight, I thought it was caused by the stress of my daily routine.

It wasn’t until July 2017 that I couldn’t ignore my symptoms any longer. When I developed a migraine and felt a tremor in my arm and eye, I knew I was about to lose consciousness. I immediately called 911.

VIEW PATIENT STORY

Selected Publications

Hong D.S., Rixe O., Chiu V.K., Forde P.M., Dragovich T., Lou Y., Nayak-Kapoor A., Leidner R., Atkins J.N., Collaku A., Fox F.E., Marshall M.A., Olszanski A.J., Mogamulizumab in combination with nivolumab in a phase i/ii study of patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 28(3): 479-488, 2022. https://www.ncbi.nlm.nih.gov/pubmed/34753777.

Marinova A.M., Reilly J.L., Wong V., Weiss S., Olszanski A.J., Metastatic melanoma with leptomeningeal disease. J Adv Pract Oncol. 12(1): 79-83, 2021.PMC7844196. https://www.ncbi.nlm.nih.gov/pubmed/33552663.

Hong DS, Rixe O, Chiu VK, Forde PM, Dragovich T, Lou Y, Nayak-Kapoor A, Leidner R, Atkins JN, Collaku A, Fox FE, Marshall MA, Olszanski AJ. Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2021 Nov 9;. doi: 10.1158/1078-0432.CCR-21-2781. [Epub ahead of print] PubMed

Wagner J, Kline CL, Zhou LL, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. Journal of Clinical Investigation, 128(6):2325-38, 2018.  PubMed

Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, et al. Investigational new drugs. 2015; 33(5):1040-7. PubMed

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, et al. Anti-cancer drugs. 2015; 26(7):785-92. PubMed

Principles of immunotherapy. Olszanski AJ. Journal of the National Comprehensive Cancer Network : JNCCN. 2015; 13(5 Suppl):670-2. PubMed

Additional Publications

85 patient satisfaction reviews

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

Overall Rating

4.9 / 5.0

Ratings Breakdown

4.9
Gives easy to understand instruction
4.9
Explains in a way you understand
5.0
Listens carefully to you
4.9
Shows respect for what you say
4.9
Spends enough time with you

14 patient comments

  • No Star Ratings Available
    March 11, 2022

    Finally having the visit was excellent.

  • 5.0
    February 15, 2022

    Dr. Olszanski and staff are top-notch, friendly and most of all concerned, about me -

  • 5.0
    October 29, 2021

    All staff were professional, knowledgeable, caring and sensitive to my needs.

  • 5.0
    September 2, 2021

    Dr. Anthony Olszanksi a true blessing) - COPD assistant) - knowledgeable - Heart warming.

  • 5.0
    September 1, 2021

    Dr. Olszanski is a caring, very competent professional! The best!

  • 5.0
    August 28, 2021

    Everything was great

  • 5.0
    July 24, 2021

    Fox Chase and Dr.Olszanski are simply the best!

  • 5.0
    June 17, 2021

    Good doctor. Good hosp. for my needs - as of now 3 yrs. still living & well.

  • 5.0
    April 10, 2021

    The doctors team were caring, professional and understanding.

  • 5.0
    March 29, 2021

    Have always good experience with Dr. O & staff - Think he's a great dr.

  • 5.0
    February 25, 2021

    Good.

  • 5.0
    January 12, 2021

    Good.

  • 5.0
    January 7, 2021

    Couldn't find a better dr. in any way. His staff is also great.

  • 5.0
    December 18, 2020

    He is cancer doctor - Seeing him for 3 yrs. He is the best around [...].